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Abstract
Background: Genome-wide association studies (GWAS) aim to identify causal variants and genes for complex
disease by independently testing a large number of SNP markers for disease association. Although genes have
been implicated in these studies, few utilise the multiple-hit model of complex disease to identify causal
candidates. A major benefit of multi-locus comparison is that it compensates for some shortcomings of current
statistical analyses that test the frequency of each SNP in isolation for the phenotype population versus control.
Results: Here we developed and benchmarked several protocols for GWAS data analysis using different in-silico
gene prediction and prioritisation methodologies. We adopted a high sensitivity approach to the data, using less
conservative statistical SNP associations. Multiple gene search spaces, either of fixed-widths or proximity-based,
were generated around each SNP marker. We used the candidate disease gene prediction system Gentrepid to
identify candidates based on shared biomolecular pathways or domain-based protein homology. Predictions were
made either with phenotype-specific known disease genes as input; or without a priori knowledge, by exhaustive
comparison of genes in distinct loci. Because Gentrepid uses biomolecular data to find interactions and common
features between genes in distinct loci of the search spaces, it takes advantage of the multi-locus aspect of the
data.
Conclusions: Results suggest testing multiple SNP-to-gene search spaces compensates for differences in
phenotypes, populations and SNP platforms. Surprisingly, domain-based homology information was more
informative when benchmarked against gene candidates reported by GWA studies compared to previously
determined disease genes, possibly suggesting a larger contribution of gene homologs to complex diseases than
Mendelian diseases.
Background
The identification of genes implicated in human disease
enables an understanding of disease mechanisms and is
essential for the development of diagnostics and thera-
peutics. Many associations have now been identified
from GWA studies. As of September 2011, the HuGE
database http://www.hugenavigator.net contained 6164
associations from 1019 published GWAS. These meth-
ods have led to the discovery of several novel genes for
complex diseases. However GWAS have not proved as
powerful as originally hoped with approximately 3061
genes reported or identified, suggesting more may be
gleaned by careful reanalysis of the data.
GWAS are designed to identify common genetic risk
factors of complex diseases and quantitative traits, that
are believed to be the result of multiple genetic and
environmental factors [1]. GWAS use high-throughput
genotyping platforms, such as SNP chips, which carry
hundreds of thousands of SNP markers. Even with mul-
tiple marker testing, GWAS have greater statistical
power to detect genetic variants that increase disease
risks than linkage analysis [2], but hundreds of SNPs
may be identified. In order to make sense of the large
amount of data acquired, most published GWAS list
only the top 20 to 50 most significant SNPs and their
nearest gene using the “most significant SNPs/genes”
approach [3], while ignoring the remaining SNPs [4-6].
A highly stringent significance threshold attempts to
correct for the number of false positives, but this con-
servative statistical approach combined with the
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selection of the nearest-neighbouring gene to the signifi-
cant SNP still has several limitations.
Phenotypes influenced by multiple genetic and envir-
onmental factors, or those with uncommon and small
effect variants, are not detected after adjustment for
multiple testing [7], thereby introducing a potentially
high false negative rate to the study. Also, variants with
larger effects might not always rank among the top mar-
kers reported when taking the most-significant SNP
approach [7,8].
A further conundrum for GWAS has been the lack of
genetic signals recovered to explain the genetic heritabil-
ity of many diseases, implying that much has been
missed due to the limitations of GWAS methodology
[9]. This missing heritability may be due to the hetero-
geneous population studied, for example the disease
may be caused by multiple rare variants; the fact that
SNPs are tested in isolation, for example if important
gene-gene interactions occur; inability to control the
environment of the patient population, for example
gene-environmental interactions may be important; or
gaps in SNP chip coverage for some regions of the
genome.
Furthermore, tagged SNPs on the platforms used in
the studies are potentially only in linkage disequilibrium
(LD) with the causal SNPs and further replication stu-
dies and sequencing is required to identify the actual
causal variant. With the advent of next-generation
sequencing, rapid follow up of multiple candidate mar-
kers or genes is possible.
The methods typically used by researchers to select
genes associated with the significant SNP assume the
disease-associated SNP is either resident in, or adjacent
to, the disease gene. But the genetic architecture of the
genome is still not well understood: work on long range
gene regulation [10] suggests distal cis-acting elements
can control genes that are not directly adjacent to the
regulatory region of the gene. For instance fibroblast
growth factor 8, FGF8, is controlled by regulatory ele-
ments within and beyond the neighbouring gene
FBXW4 [11]. Therefore, the disease gene may be near
the significant or causal SNP but may not be the closest
gene to it, i.e. the causal SNP is in a regulatory region
that acts distally on the disease-causing gene. In these
cases, the simplistic approach currently used for SNP-
to-gene mapping is limiting and the search space should
be extended to include additional nearby genes that may
play a role in the phenotype.
Clearly new approaches are required to utilize the
valuable but noisy data from GWAS. In order to avoid
“throwing the baby out with the bathwater”, the statisti-
cal significance threshold can be decreased to study a
much larger sample of SNPs which may potentially be
associated with the disease. Although, this reduces the
power of the study, these less significant SNPs can then
be sifted using other information. Several approaches
have been suggested. Genetic information can be used
to “weight” SNPs according to their plausibility. Infor-
mation can be in the form of genome-wide linkage from
population data [12,13]; or prior probabilities of associa-
tion in significance calculations [14,15]. In addition to
genetic data, biomolecular data such as information on
protein function and protein-protein interactions can
provide valuable information to distinguish associated
loci from noise.
Gentrepid is a second generation candidate gene pre-
diction system tool that draws on two types of func-
tional data to group genes [16,17]. The Common
Pathway Scanning (CPS) module is a Systems Biology
method based on the assumption that common pheno-
types are likely to be associated with proteins that par-
take in the same complex or pathway [18]. In other
words, disease-causing genes for a specific phenotype
are more likely to interact with other phenotype-specific
disease genes [19,20]. Potential disease genes are pre-
dicted by identifying all proteins within phenotype-asso-
ciated loci that are part of a pathway or complex.
The second Gentrepid module is Common Module
Profiling (CMP), a technique based on the principle that
candidate genes have similar functions to disease genes
already determined for the phenotype [21]. A unique
feature of CMP is that it uses domain-based compara-
tive sequence analysis to identify proteins with potential
functional similarity. In the field of candidate disease
gene prediction, genes are often treated as single func-
tional units, but translated proteins fold into discrete
globular structures of limited size called domains [22].
Sequence-determined autonomous folding of domains
into conserved compact three-dimensional structures is
proposed to occur through hydrophobic collapse. A
domain-based sequence comparison approach has sev-
eral advantages over protein-based ones. Multiple
domains, each with their own biochemical function, are
often combined into a single gene to encode its entire
function in a modular fashion similar to LEGO blocks
[23-25]. Dissection of a gene into domains thus poten-
tially provides a more fine-grained approach to func-
tional assignment than can be achieved on a gene-by-
gene basis. In addition, a particular isoform of a gene
may be implicated. At the phenotypic level, functional
clustering can be used to advantage as there are fewer
building blocks than genes. The number of human
genes stands at 25,000 to 35,000 [26], and the estimated
size of the proteome ranges from 90,000 [27] to
1,000,000 [28]. In comparison, the fold repertoire of
domains in the planetary proteome has been estimated
at between 1000 and 5000 folds [29-31]. A domain-
based approach also enables better detection and
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annotation of protein features. Because structure is con-
served over sequence, domain-based sequence compari-
son searches have been shown to be more accurate than
full-sequence searches [32]. Using the Pfam library of
Hidden Markov models [29], domains can be assigned
to approximately 69% of human proteins which allows
functional inference for around 54% of the human gen-
ome. Prioritisation of the genes predicted from the mod-
ules is based on the statistical significance of the results.
Here we developed and benchmarked several proto-
cols for analysing GWAS data effectively using the well-
studied WTCCC data set on seven diseases. This data is
employed in two manners: firstly using known disease
genes for a particular phenotype to seed the search; and
secondly using an agnostic approach which searches for
de novo relationships between multiple loci. Predictions
are then benchmarked against known disease genes, and
genes suggested by the WTCCC study. The results
show that analysis of more SNPs and consideration of
more genes around each SNP replicate data from pre-
vious studies more effectively. The system was capable
of extracting significantly associated genes from those of
lower significance, as well as known and novel candidate
disease genes using either a priori genetic knowledge or
de novo analysis.
Results
To test the ability of Gentrepid to select and prioritise
valid disease gene candidates from the SNPs of GWAS,
we performed a series of analyses on data from case-
control studies from the WTCCC [33]. Most early
GWAS used the Affymetrix chip set with approximately
500,000 known SNPs (Affy500k). We extracted 459,231
autosomal SNPs from the chip set for further analysis as
detailed in the methods.
Average number of SNP associations per phenotype
First we selected appropriate significance thresholds for
GWA SNPs that are associated with the phenotypes of
interest by increasing the cut-off of the Cochran-Armi-
tage association p-values. Although the data quality var-
ies depending on the phenotype, four consistent
thresholds were used for ease of comparison: a weakly
significant set (WS, pGWA ≤ 10
-3), a moderately-weak
significant set (MWS, pGWA ≤ 10
-4), a moderately-high
significant set (MHS, PGWA ≤ 10
-5), and a highly signifi-
cant SNP set (HS, pGWA < 5 × 10
-7). Table 1 sum-
marizes the average number of SNPs above each of the
significance thresholds that were associated with the
phenotypes. On average, 30 highly significant SNPs were
associated with a phenotype and this rose to over 800
SNPs for the weakly significant data. We then clustered
co-located SNPs into what we termed an “associated
locus” (See Methods). Significant SNPs show strong
clustering, with 50-60% of significant SNPs clustering in
phenotype-specific loci, with an average of 3 SNPs per
cluster. The HS threshold had, on average, 7 associated
loci per phenotype whereas the average number of asso-
ciated loci for the WS threshold was over 400 (Table 1).
Gene selection around associated loci
To further investigate the relationship between pheno-
type-associated loci and nearby genes, genes were
selected within a series of pseudo-intervals constructed
around loci using one of two major assumptions (Figure
1). The first assumption, which gathers genes based on
proximity to the associated locus, we termed the Near-
est Neighbour (NN) approach. To enable discovery of
genes subject to longer range regulation, we adopted an
additional distance-based Bystander (BY) approach
whereby genes were captured from an interval of fixed
size created around each locus. For the NN approach,
three sets of genes were created: a set containing genes
with loci internal to the gene termed the resident set; a
second set with loci directly adjacent to the gene,
termed the nearest set; and a third set with the loci
either resident in, or directly adjacent to, the four near-
est genes, termed the adjacent set (Figure 1). NN sets
Table 1 Average number of SNPs, loci and genes per
phenotypes used in this study with significant
association p values and associated annotated genes in
Gentrepid
Level
WS MWS MHS HS
p ≤ 1e-
3
p ≤ 1e-
4
p ≤ 1e-
5
p < 5e-
7
SNPs 804.29 160.29 56.71 29.14
Loci 446.86 84.43 18.71 7.29
Total Genes BY 1 Mbp 3875.57 870.86 175.29 87.43
0.5 Mbp 2140.00 477.29 106.00 57.29
0.1 Mbp 654.57 148.43 43.71 23.00
NN Adjacent 1412.14 292.43 62.29 26.14
Nearest 452.86 91.00 22.29 10.14
Resident 198.71 42.57 11.43 5.43
Annotated
Genes
BY 1 Mbp 2285.29 528.86 116.43 61.57
0.5 Mbp 1275.57 300.43 73.14 41.57
0.1 Mbp 426.43 103.43 32.00 16.57
NN Adjacent 803.14 172.00 40.71 17.57
Nearest 285.71 59.00 15.57 6.14
Resident 155.29 33.43 8.86 3.57
Column abbreviations: HS, highly significant; MHS, moderately-high
significance; MWS, moderately-weak significance; WS, weakly significant. Row
abbreviations: SNPs, average number of implicated SNPs per phenotype; Loci,
average number of SNP clusters per phenotype; “Total Genes”, the average
number of genes per phenotype in the designated constructed pseudo-
intervals; “Annotated Genes”, the average number of genes per phenotype in
the designated constructed pseudo-intervals with Gentrepid annotations.
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are not distance based. For the BY approach, three
pseudo-intervals of different sizes were tested: genes
were pooled from flanking intervals of 0.1 Mbp, 0.5
Mbp or 1 Mbp in width around loci (Figure 1).
The 24 implicated search spaces per phenotype con-
structed using multiple SNP significance thresholds and
gene selection methods ranged in size from 2 to 4431
genes: up to 10% of the genome. We have previously
shown that candidate gene prediction by Gentrepid in
such large search spaces is computationally feasible [17].
As shown in Table 1, more genes are associated with
the phenotype-specific loci in the two larger bystander
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Figure 1 Summary of GWAS analysis methodology. (A) Double filter pipeline for GWAS data. The Genetic test filters for the disease-
associated SNPs which are then mapped to genes. The Bioinformatics test, using Gentrepid, filters the genes for likely disease candidates. (B)
SNP-to-gene approaches. The nearest neighbour approach consists of three sets: the resident set containing genes with SNPs internal to gene
boundaries; the nearest set containing genes with SNPs internal or directly adjacent to the gene; and the adjacent set containing the four
nearest genes to a SNP. The bystander approach consists of three sets where genes on both strands around SNPs were pooled from flanking
intervals of fixed width. The sets include a 0.1 Mbp interval, 0.5 Mbp and 1 Mbp. Genes are represented as rounded rectangles and SNPs are
marked as blue bars. (C) Gentrepid prediction method summary. A gene search space derived from GWAS data can be supplemented with
known disease genes (seeded) or used stand-alone (ab initio). Genes involved in common pathways (CPS) or sharing common domains (CMP)
within these search spaces are extracted by the system. Genes are prioritized based on the likelihood of genes with these properties occurring
randomly.
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intervals (0.5 Mbp and 1 Mbp). However, the adjacent
NN gene set usually contains more genes than the smal-
lest BY interval for each phenotype (0.1 Mbp), as often
one of the adjacent genes is located farther than the 50
Kbp distance threshold used (0.1 Mbp/2). Genes in the
adjacent set are on average 362 Kbp (178-388 Kbp)
away from the associated SNP, whilst genes in the near-
est set are on average 90 Kbp (20-96 Kbp) away.
Constraints on genomic coverage
As a baseline, we wished to establish how genomic cov-
erage by the Affy500K SNP chip set used in the
WTCCC study depended on the approaches and
assumptions used, and if these genes were represented
in Gentrepid by associated pathways and domains.
Figure 2 shows coverage of the human genome by the
Affy500K chip set using the three gene selection meth-
ods for each of the NN and BY approaches tested. Here
we define genes that are present in RefSeq [26] as “char-
acterized” genes and those that have either a domain
predicted through Pfam [29], or pathways and interac-
tions partners in Gentrepid as “annotated”. By selecting
only the nearest gene to the associated SNP, as currently
done in GWAS (nearest NN set), only 76% of character-
ized genes are associated with a SNP. Gene coverage
increases to 90% if we associate nearest genes in the 3’
and 5’ direction on both strands with the SNP (adjacent
NN set). Using the BY approach, gene coverage
increases with interval size, ranging from 96% (0.1 Mbp)
to 99.4% (1 Mbp) of characterized genes. SNPs on the
Affy500K chip sets are randomly distributed across the
genome, and ignore LD patterns. We confirmed this by
observing that the density of SNPs on the chip sets is
similar to the density of SNPs across the genome from
dbSNP (data not shown). The Affy500K chip set’s cover-
age of the genome has been shown to be poorer than
other platforms that attempt to capture as much genetic
variation as possible through LD-based tagging [34].
Comparative overview of candidate gene predictions
To assess the ability of the two Gentrepid modules (CPS
and CMP) to independently extract positional candi-
dates from less significant data, we analysed the GWA-
implicated pseudo-intervals chosen using both the NN
and BY assumptions at the different levels of stringency.
Two modes of input, referred to as “seeded mode” and
“ab initio mode” were used to determine the common
properties of phenotype-specific genes within the six
gene sets for each disease. Seeded mode is assisted by
phenotype-associated genes from OMIM [35] (Addi-
tional file 1, Table S1). The “known” disease genes were
defined as those determined prior to GWAS of these
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Figure 2 Genomic coverage of the entire Affymetrix 500 K chip set SNPs (purple, left-most bar) and annotated genomic coverage of
Gentrepid (other bars) when pseudo-intervals are constructed around the SNPs using each approach tested. The bar graph on the left
shows how many characterized genes in the genome are covered or represented for each approach tested. The approach most commonly used
in GWAS, nearest, is indicated with an *. The Affy Chip set only covers 80% of the genes in the genome using this method. The BY approach has
the higher total genome coverage, and this also holds when looking at the annotated coverage. The Venn diagram on the right shows the total
overlap between the annotated (15,702) and characterized genes (27,499) in Gentrepid, with the greater portion of annotation from domain
information. Parsed domains refer to the genes with Pfam domain information.
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diseases, and therefore are restricted to OMIM entries.
Ab initio mode uses only genes pooled from the SNP-
associated intervals: no additional genetic data beyond
the GWA-implicated loci is required.
We compared the average number of significant pre-
dictions made by each of the modes and modules and
the complementarity of these predictions (Table 2)
across all search spaces tested. A CPS prediction was
considered significant at p < 0.05, whilst CMP predic-
tions were determined through scores/statistical tests
described in detail in the methods section. Ab initio
mode had, on average, more predictions when compared
to seeded mode for the same gene search space set, indi-
cating that there was novel information in the genetic
data that was not represented by the known disease
genes: a success for the GWAS methodology. In some
instances, there were no predictions made by the seeded
mode, suggesting earlier studies were either on the
wrong track, or their results are limited to the studied
family. Interesting differences were noted between the
two bioinformatic methods depending on the signifi-
cance of the SNPs used. Fewer predictions were made
in the nearest and resident approaches of the HS and
MHS thresholds, suggesting that the use of more gener-
ous thresholds may be detecting weaker effects. CPS
seeded made more predictions than CMP seeded. CPS
ab initio made, on average, more predictions than CMP
ab initio for the WS and MWS data. For the MHS and
HS thresholds, CMP ab initio made more predictions
than CPS ab initio except for the HS nearest set where
CMP ab initio made no predictions. For the stringent
thresholds, the number of predictions was similar for
each module.
A summary of the proportion of the total number of
significant predictions made by each module is repre-
sented in Figure 3. For seeded predictions, CPS made
more predictions than CMP, as shown by the distinct
data points on the left hand side of Figure 3. CPS pre-
dicted between 59-100% of total seeded predictions,
while CMP only predicted between 12-43% of total
seeded predictions. However, at most 12% of these pre-
dictions are common to the two modules (joined dia-
monds at bottom). In the ab initio analysis, CMP made
a larger contribution to the number of predictions com-
pared to the seeded mode. CPS predicted between 14-
100% of ab initio predictions, while CMP predicted
between 27-88% of ab initio predictions. But again, the
two modules were relatively independent with 12% of
these predictions in common. The percentage of ab
initio predictions made by each module varied
Table 2 Average number of gene predictions made by Gentrepid modes and modules
Mode SNP/gene CPS CMP CPS + CMP
Approach WS MWS MHS HS WS MWS MHS HS WS MWS MHS HS
Seeded BY 1 Mbp 29.14 6.00 2.29 0.71 15.43 3.86 0.71 0.43 42.86 9.43 3.00 1.14
0.5 Mbp 12.29 5.29 2.00 1.29 9.00 2.86 0.57 0.29 20.71 7.71 2.57 1.57
0.1 Mbp 6.71 3.00 1.71 1.00 3.14 1.00 0.29 0.00 9.57 3.57 1.86 1.00
NN Adjacent 19.14 6.00 1.57 1.43 6.86 1.57 0.43 0.00 25.29 7.00 1.86 1.43
Nearest 10.86 2.57 1.43 1.00 3.00 0.86 0.29 0.00 13.71 3.29 1.57 1.00
Resident 4.29 1.43 1.00 0.57 1.29 0.43 0.14 0.00 5.57 1.86 1.14 0.57
Ab initio BY 1 Mbp 105.00 27.14 6.86 5.86 57.57 14.71 12.57 10.14 157.14 40.71 17.43 14.29
0.5 Mbp 41.29 17.43 5.86 2.86 30.71 12.71 8.57 10.43 70.00 29.57 14.43 11.86
0.1 Mbp 28.57 6.71 2.00 0.57 12.14 10.00 7.86 3.57 38.14 16.71 9.86 4.14
NN Adjacent 59.57 13.86 2.14 0.71 26.86 8.71 5.29 2.00 81.14 21.29 6.71 2.71
Nearest 28.71 5.14 1.00 0.57 10.86 2.00 1.71 0.00 37.43 6.86 2.71 0.57
Resident 13.00 2.57 0.29 0.00 9.71 0.86 0.57 0.00 21.00 3.14 0.86 0.00
Seeded and ab initio BY 1 Mbp 105.00 27.14 6.86 6.57 72.43 18.43 13.29 10.57 170.14 44.00 18.14 15.43
0.5 Mbp 41.43 17.43 5.86 3.57 39.57 15.57 9.14 10.71 78.43 32.00 15.00 12.86
0.1 Mbp 28.57 7.00 2.29 1.29 15.29 11.00 8.14 3.57 40.57 17.57 10.29 4.86
NN Adjacent 59.57 13.86 2.29 1.71 33.43 10.29 5.71 2.00 86.57 22.29 7.14 3.71
Nearest 28.71 5.29 1.71 1.14 13.86 2.86 2.00 0.00 39.86 7.57 3.57 1.14
Resident 13.00 2.71 1.00 0.57 10.71 1.29 0.71 0.00 22.00 3.71 1.71 0.57
Each cell represents the number of predictions averaged across the seven phenotypes made by the mode and module. Column abbreviations: HS, highly
significant; MHS, moderately-high significance; MWS, moderately-weak significance; WS, weakly significant; CPS, common pathway scanning module; CMP,
common module profiling. Row abbreviations: Seeded, mode using known disease gene information as seeds; Ab initio, blind approach mode; BY, bystander
approach; NN, nearest neighbour approach. The total number of predictions made by Gentrepid for each significance threshold and SNP/gene approach are
bolded. All results have been filtered on significance. For CPS, pathways reach a significance threshold of p < 0.05 based on Fishers exact test. For CMP seeded, a
threshold of 0.4. For CMP ab initio, a threshold of c2max_unique > 105 and c2 min > 7.88 for multidomain proteins and c2 min > 100 for single domain proteins.
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depending on the gene selection method and signifi-
cance threshold, as shown by the less distinct separation
of points on the right hand side of Figure 3. For the WS
sets, CPS made more ab initio predictions; while for the
MHS and HS sets, CMP made more predictions except
for the smaller nearest and resident sets. The fewer pre-
dictions by CMP ab initio could reflect one of two
things: true biological signals in complex diseases are
missed in these smaller sets because candidate genes
with long range effects are not included, or that the pre-
dictions made in the smaller sets with fewer genes fail to
reach significance in our tests. Seeded and ab initio pre-
dictions are most congruent for CPS, with shared pre-
dictions comprising between 16-62% of total CPS
predictions. For CMP, the predictions made by the
seeded and ab initio modes are dissimilar, with 0-3%
overlap in predictions. The congruency in predictions
between CPS seeded and ab initio indicates that CPS
works well as a search tool because the same pathways
are being selected by the ab initio method without the a
priori knowledge supplied to the seeded method. CPS is
also a good discovery tool as there are novel predictions
made by ab initio that were not detected by the seeded
method. On the other hand, the fewer similar predic-
tions made through the CMP seeded and ab initio mod-
ules might reflect differences in candidate gene
significance filtering, or perhaps that CMP ab initio is
making many more novel predictions and is a much
stronger discovery tool for GWAS data. As the pathways
utilized by CPS are often elucidated as part of the
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disease discovery process, the domain-based CMP
approach may be a superior source of novel predictions
for poorly characterised diseases when implemented
using the agnostic ab initio approach.
Benchmarking against validation sets
As Gentrepid is intended as a discovery tool, there is
currently no absolute way to determine if the candidate
genes selected by the Gentrepid modules are indeed true
positives without further genetic and molecular analyses
on patients with the genotype. As a proxy, we tested
Gentrepid on two datasets containing either known cau-
sal genes or genes that have a high probability of being
causal. The first set consisted of known disease genes
and loci from the phenotype data; whereas the second
set of genes were implicated by the WTCCC as candi-
dates. The ability of Gentrepid to extract and prioritise
the genes in these sets was tested (Figure 4). In order to
determine the overall performance of the modules being
tested on the validation set, we calculated the sensitivity,
specificity and enrichment ratios of each of the methods
for each significance threshold (Figure 5).
Our first validation set consisted of 97 known disease
genes collated from OMIM for the 7 diseases from the
WTCCC study (Additional file 1, Table S1). Of these
97 genes, up to 29 were within WTCCC-implicated loci
depending on the SNP-to-gene selection method
employed and 7 of these genes were in highly significant
loci (Additional file 1, Table S2). However the remain-
ing known disease genes, constituting 70% of genes
extracted from OMIM, were not in the search spaces at
all. The lack of congruence between previous studies
and the WTCCC data could be due to several factors
which include differences in study design, differences in
studied populations leading to allelic and locus hetero-
geneity, or true genetic differences. Our second valida-
tion set consisted of the WTCCC-implicated candidates,
a total of 62 genes, from both significant and modestly
associated SNPs [33] (Additional file 1, Table S1). Of
these genes, 47 were within the search space, but only
39 were Gentrepid annotated genes. Of the 39 genes in
at least one search space, 16 were in highly significant
loci (Additional file 1, Table S3).
The ability of CPS to predict and prioritise known dis-
ease genes is shown in Figure 4A. A predicted gene is
assigned an ordinal priority based on the statistical sig-
nificance of the pathway it shares with other phenotype-
implicated genes and thus has a rank equal to other
candidates in the same pathway. The majority of known
disease genes were in the highest ranked pathway for
the phenotype. Known disease genes comprised 62% of
all seeded predictions and 42% of all ab initio predic-
tions. Most genes in the 0.1 Mbp and adjacent
approaches were ranked 1st, but generally the gene
selection method used had little effect on priority. Some
deterioration of the signal is apparent for the least sta-
tistically significant data (WS), when the more demand-
ing ab initio method is employed; or when larger search
spaces are used. The ability of CPS to prioritise
WTCCC phenotype-specific candidates is shown in Fig-
ure 4B. Despite being confronted with increasingly large
search spaces, CPS is still able to extract biologically
relevant genes from the increasingly less significant
genetic data. Genes associated with the most statistically
significant SNPs were primarily ranked first, constituting
up to 66% of all predictions in seeded mode and 46% of
all ab initio predictions. Of the 16 annotated WTCCC
candidates in the HS sets: 4 candidates from the adja-
cent set were predicted by CPS seeded and given the top
priority; 3 genes were predicted and given the top prior-
ity by CPS ab initio, and a fourth gene was ranked 2nd.
Overall for CPS, genes in both validation sets were
ranked first when the 0.1 Mbp or adjacent gene selec-
tion methods were used.
The ability of CMP to prioritise known disease genes
is shown in Figure 4C. A predicted gene is assigned an
ordinal priority based on its score in CMP seeded, and
the c2 min score of CMP ab initio. Only 7 pairs of the
phenotype-specific known disease genes share common
domains, so CMP seeded was not expected to make
many predictions based on the available input. Even so,
only a single known gene was predicted by CMP seeded,
TCF2 for the T2D phenotype which shares hepatocyte
nuclear factor 1 domains HNF-1B_C (PF04812) and
HNF-1_N (PF04814) with known disease gene TCF1.
CMP ab initio predicted CARD15/NOD2 for the CD
phenotype, but other predictions did not pass the
required thresholds. The ability of CMP to prioritise
WTCCC phenotype-specific candidates is shown in Fig-
ure 4D. CMP seeded only predicts HHEX for the T2D
phenotype based on the homeobox domain it has in
common with known disease genes IPF1 and PAX4.
CMP ab initio predicted a total of 6 of the 39 WTCCC
candidates, ranking the predicted genes 1st to 10th.
Overall, CMP prioritised the WTCCC validation set
genes in the top ten in a manner that was in rough
agreement with SNP significance.
Further to the prioritisation results, the specificity,
sensitivity, and the enrichment ratio (ER) metrics allow
for an overall quantitative comparison of the perfor-
mance of the individual modes and modules (Figure 5,
Additional file 1, Table S4). The sensitivity of the sys-
tem ranged between 0.09 and 1. CPS in both seeded and
ab initio mode had higher sensitivity scores compared
to CMP. CPS ab initio generally had the highest sensi-
tivity compared to the other modes and modules; hold-
ing true for both validation sets. Using the known WS
set for validation, CPS seeded had a sensitivity that
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ranged between 0.35 to 0.50, while CPS ab initio was
between 0.40 and 0.67. CPS had higher sensitivity in the
NN gene selection sets compared to the BY sets. For
CMP, the sensitivity was low due to few predictions.
The specificity of the system ranged between 0.55 and 1.
For CPS and CMP, specificity was less for the NN gene
selection sets compared to the BY sets. For instance for
the WS SNPs validated against known disease genes,
CPS seeded had a specificity between 0.97 and 0.99 for
the BY gene sets but only 0.92 to 0.97 for the NN gene
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the (A) Known disease gene set and (B) WTCCC-implicated gene candidates; CMP predictions against the (C) Known disease gene set
and (D) WTCCC-implicated gene candidates. The data sets are shaded based on the significance of the underlying SNP set: yellow for HS,
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sets. The ER of the system components varied between
1 (no enrichment) and 24.29 fold enrichment. For CPS
seeded ERs decreased with NN gene set size, while for
CPS ab initio, the maximal ER was for the 0.5 Mbp BY
gene set for the WS SNPs, but the smaller 0.1 Mbp BY
gene set for the MWS, MHS and HS SNP sets. Similar
results were obtained with the WTCCC validation set.
CMP seeded and ab initio benchmarked poorly against
the known validation set, but CMP seeded performed
much better on the WTCCC validation set. As for CPS,
the largest ERs for CMP seeded were returned for the
MWS and MHS data sets using the adjacent gene sets,
and similar ERs for all the remaining approaches (except
the resident) using the WS data set.
Comparison to random controls
As another test of the system, we compared predictions
based on the WTCCC SNPs with predictions based on
randomly generated SNP data. This test allows us to get
a better handle on variables such as which gene selec-
tion sets are optimal, or if the signal-to-noise ratio
begins to decrease as we decrease the significance level,
as would be expected. We ran 1000 permutations of
randomly selected SNPs for each disease, mode (seeded/
ab initio) and module (CPS/CMP) set. As an indicator
of performance, we calculated the log ratio of the num-
ber of predictions generated from the real data to the
average from the randomly generated sets (Figure 6). A
positive ratio indicates better performance on real versus
random data, a neutral score no difference from ran-
dom, and a negative ratio poorer performance. For
example, if the WTCCC SNPs are really phenotype-spe-
cific at a particular significance level, we would expect a
larger number of predictions by the real data than by
random SNPs.
When predictions made in seeded mode using pheno-
type-related SNPs were compared to predictions based
on random SNPs across the different gene selection sets,
the performance of the system was mode and module
specific. CPS seeded performed best on the NN sets.
CMP seeded performed best on BY sets, but CMP ab
initio performed best on the NN sets. CPS ab initio was
the worst performing module, mode combination.
Seeded mode performs best across all SNP/gene
approaches, whilst ab initio performs the best for the
NN sets. CPS performed the best for the NN sets, while
CMP performs well across all SNP/gene approaches.
When predictions made in seeded mode using pheno-
type-related SNPs were compared to predictions based
on random SNPs across the significance thresholds, CPS
had a positive ratio for the MWS-, MHS- and HS-impli-
cated loci. CPS ab initio had a positive ratio for the
MHS and HS sets. For CMP, both seeded and ab initio
modes generally had positive ratios for the MHS and
MWS set, neutral performance for the HS set, and a
negative ratio for the WS set. In summary, the best per-
formances were on the MHS and MWS thresholds
across all the modules.
The poor performance of CPS on the WS sets in these
tests using random data as compared to the benchmarks
performed on previously discovered disease genes was
surprising. Examining the random data shows that non-
specific pathways generated a disproportionate number
of CPS predictions which led to an increased rate of
false positives. An example is the cytokine-cytokine
receptor pathway from KEGG which retrieves generic
cytokines which are not cognate ligands for the retrieved
cytokine receptors. Using the MHS data, the system per-
forms better than random when pathway data is avail-
able because of the higher statistical significance of the
SNPs in this dataset, but the number of loci is diminish-
ing to the point where it is not possible for CPS to
make a prediction. This is also a reflection of the depen-
dence of the analyses on the quality of current databases
and annotations.
The same significance thresholds used in CMP ab
initio across all the SNP/gene approaches do not take
into account that the appropriate threshold may be
search space dependent, as there are more genes in sets
such as the 1 Mbp compared to the adjacent. Post-fil-
tering the candidate genes based on the number of
times they appeared in the random simulations was one
approach we took to reduce the number of false posi-
tives in the phenotype-specific predictions. Fewer pre-
dictions were filtered from the NN sets for all
phenotypes, which indicates there was most likely less
noise in these search spaces. The gene predictions in
the more selective sets were robust when filtered against
the random simulations, suggesting genuine predictions.
As in the case of CPS, CMP ab initio predictions
require multiple loci which are fewer in the genetically
more selective MHS and HS sets.
Comparison to other systems
Our system focuses on the use of the protein knowledge
base for predictions of candidate disease genes from
implicated regions but there are other tools and meth-
ods that utilise alternate annotation information to per-
form predictions. Previously, we compared Gentrepid to
6 other candidate gene prediction systems using linkage
analysis data against GWA results for type II diabetes
[17]. Here, we compared the performance of our system
on the GWAS data to two other candidate gene predic-
tion tools currently available online: GRAIL [36] and
WebGestalt [37]. GRAIL [36] identifies relationships
amongst genomic disease regions by text mining
PubMed abstracts and assessing gene relatedness. Web-
Gestalt [37] performs gene set enrichment analysis given
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a list of genes or SNPs which it maps to genes using the
array specific list of genes. We used the HS and MHS
SNP sets to perform our analyses. Because GRAIL
accepts a list of SNPs or disease regions and performs
its own SNP-to-gene mapping based on LD, we used
the gene set generated by GRAIL to perform the
remainder of the analyses. Using LD to cluster the SNPs
into distinct loci returned similar, but not always, identi-
cal results to the naive clustering method used in this
study (Additional file 1, Table S5). For instance, the
SNPs in the MHC locus are all in high LD over long
stretches, yet the region is interrupted by multiple
recombination hotspots [38]. As a result, the naïve clus-
tering method returns multiple associated loci for the
MHC region, while the LD method clumps all the SNPs
into one large associated locus. The gene search spaces
also differed between the LD method and the adjacent
mapping implemented for the MHS and HS SNP sets.
The average number of genes per locus varies for each
disease, ranging from 1 to 27 genes per associated
region (data not shown) with the LD approach. As
described, the adjacent mapping would have at most 4
genes as candidates. Also, the adjacent mapping does
not restrict the genes to be in LD with the associated
locus so for some cases genes at greater distances from
the associated region are analysed. An example is two
Ephrin receptors (EFNB2 Ephrin-B2 and EPHA7 EPH
receptor A7) which Gentrepid predicted as candidates
for coronary artery disease in the adjacent gene set.
Gentrepid made more predictions for the adjacent gene
search space than it did for the LD search space for the
HS SNP set, but made fewer predictions for the adja-
cent mapping in the MHS SNP set than from the LD
(Additional file 1, Table S6). This is most likely due to
a loss of power as the size of the gene set increases.
To compare the available web-based methods, we ran
Gentrepid, GRAIL and WebGestalt on the HS and MHS
sets for each disease using the LD mapped gene search
spaces created by GRAIL. We considered a result to be
a prediction if the statistical significance of the annota-
tion returned was p < 0.05. Overall, WebGestalt and
GRAIL returned more candidate gene predictions and
more regions with predictions than Gentrepid (Addi-
tional file 1, Table S7). But many of the predictions
made by GRAIL and WebGestalt were genes from the
same locus, indicating a higher false positive rate. We
also calculated the sensitivity, specificity and enrichment
ratio of the different methods using the WTCCC candi-
date genes as the validation set (Additional file 1, Table
S8). Specificity was high for all the systems, so for more
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insight into performance we compared the sensitivity
using the MHS set (Figure 7). GRAIL had the highest
sensitivity with the PubMed abstract method, than when
given seeded regions. Gentrepid CPS had similar sensi-
tivities for both ab initio and seeded modes, which
remained the same when the p-value threshold was low-
ered (p < 0.01). Of note, the sensitivity values are much
lower across all the methods using genes selected by
linkage disequilibrium compared to the different map-
ping approaches considered in this study.
Discussion
GWAS are a valuable approach to identification of loci
involved in disease phenotypes. In this work, we devel-
oped a method for analysing GWA data that uses a
combined statistical and bioinformatic protocol to sort
the genotype-phenotype signal from the noise. We
adopted a double sift approach, based on genetic and
biological knowledge, to identify likely causal genes in
selected sets of phenotype-associated SNPs comprising
up to 0.2% of genotyped SNPs. This method has
revealed hidden information that was missed when the
analysis relied solely on the SNPs of highest statistical
significance. This may explain some of the missing her-
itability in GWAS [9]. The biological information
employed utilizes pathways and domain-based similarity
to find relationships between multiple genes associated
with genetic data for specific phenotypes.
Value of systematic SNP significance investigation
The lower statistical thresholds used in the study cap-
ture a large number of phenotype-SNP associations that
were not revealed in previous studies. Although lower-
ing the statistical threshold may increase the number of
false positive SNPs reported, regions that were otherwise
missed by the high significance threshold cut-off
adopted in the original study clearly contain phenotype-
specific information that departs from random data. The
lower statistical significance of these associations may
reflect either the rarity of the alleles or those with small
effect sizes. Both these types of alleles are believed to be
major contributors to the disease phenotypes as the
majority of common SNPs associated with the pheno-
types studied fail to explain the heritability of many dis-
eased individuals [9]. The replication of known loci in
the data of lower significance supports the value of this
approach.
Selecting gene sets associated with each SNP set
Some studies have suggested [10,11], for example those
on long range regulation of genes, that the location of
controlling elements may be distal to the actual tran-
scripts and protein-coding regions themselves. For this
reason, gene sets were selected around SNPs in six dif-
ferent ways to investigate how these SNP to gene selec-
tion assumptions affected predictions. The different
assumptions, such as the bystander approach, increase
the study’s gene coverage of the genome, potentially
capturing longer range associations between SNPs and
genes. Whether these longer range associations are reg-
ulatory or arise from linkage disequilibrium remains an
open question.
An unavoidable accompaniment of using distance-
based gene selection approaches is the introduction of
noise into the results which therefore requires stricter
filtering. A single associated locus captures a set of at
most 4 genes in the proximity-based NN approaches,
but in the distance-based BY approaches, some loci that
are in gene dense regions link to many more genes. In
the largest gene sets tested, on average, there were 16
genes to a 1 Mbp locus. Many of the predictions made
by Gentrepid are for the largest loci: 1 Mbp BY, 0.5
Mbp BY and adjacent NN. In many instances the pre-
dicted gene is not the nearest gene to the implicated
SNP (Table 2). This may truly demonstrate long range
regulatory effects, or alternatively the inclusion of more
genes may simply increase the chances of predictions.
The most successful approaches, as judged by the
enrichment ratios, specificity and sensitivity measure-
ments on the validation sets, are the adjacent and 0.1
Mbp approaches. Both these sets have similar search
space sizes and contain less noise than the larger BY
sets. However, there may be an element of self-selection
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in this result, if geneticists typically only scan the
immediate vicinity of the locus studied for the disease
gene. Even so, the more generous SNP/gene assump-
tions did not unduly lower the performance of the sys-
tem, with multiple instances of consensus amongst
predictions across the different sets [39]. Enrichment
ratios varied from 15 to 25 depending on the thresholds.
For the maximal search space of 3000 genes, this is
roughly equivalent to 120-200 disease candidates per
phenotype: a number that is feasible to scan with cur-
rent sequencing technologies.
Performance in seeded versus ab initio mode
Predictions based on known disease genes are inherently
limited by what is already known about a phenotype. In
seeded mode, Gentrepid is an effective tool to assist in
the discovery of phenotype-related genes in novel loci.
The ab initio methodology is a powerful discovery tool
for finding novel genotype-phenotype relationships for
complex diseases. For diseases with Mendelian inheri-
tance, ab initio mode is also likely to be advantageous if
only a small percentage of cases arise from known dis-
ease genes.
CPS seeded mode is generally a more powerful discov-
ery tool when retrieving novel genes associated with
pathways involving disease genes previously linked to
the phenotype. In this mode, the candidate gene search
space is enriched for known disease pathways, increasing
the chances of retrieving genes that share this pathway.
In contrast, ab initio mode only considers genes within
the candidate loci and excludes many of the confirmed
disease genes: a more agnostic approach which may be
informative.
In addition to the constraints described above for ab
initio predictions, the success of Gentrepid predictions
using known disease genes depends on how informative
these genes are for the phenotype. A number of factors
influence the system’s ability to make predictions
including the quality of the input GWA data for the
specific phenotype, and genome coverage of pathways
specific to phenotype. Even when the entire genome is
considered, only 57% of characterized genes have Gen-
trepid annotations and are thus potentially predictable
as candidates. Most of this coverage is due to Pfam
domains, while pathways cover up to 20% of annotated
genes (Figure 2). Thus the system is unable to make
predictions for around 40% of the genome which may
or may not be associated with the phenotype. Outside
these phenotype-specific constraints, a threshold num-
ber of loci are required for the prediction to be signifi-
cant. As discussed, generic pathways that are not highly
informative or specific, increase the chances of random
predictions by CPS, as do common domains by CMP (e.
g. Ras PF00071).
Performance of CMP versus CPS
In our previous benchmark, which used a dataset of
Mendelian diseases developed by Turner et al [40], we
found CPS more effective in retrieving candidates. Using
GWA data for complex diseases, the domain-based
CMP module of Gentrepid made many plausible predic-
tions. The auto-detected domain comparison in CMP
removes the need to rely on the current annotations of
human proteins, which are still lacking [41]; or on
whole gene sequence-similarity which is less accurate
[42]. However it was interesting that CPS was still more
effective in replicating known disease genes including
some loci where a disease gene has not previously been
allocated. Of the 29 known disease genes, 16 were pre-
dicted by CPS. The predictions made by CMP may be
spurious, although the random simulations suggest
otherwise. Alternatively, the superior performance of
CPS in replicating known disease genes may be a selec-
tion effect. The genes within the sets were determined
to be disease causing based on known disease pathways
and interactions. Specifically, geneticists may have been
searching for disease genes for complex diseases based
on experience gained from Mendelian diseases. In the
case of Mendelian diseases, this approach may apply, as
penetrance is high for monogenic disorders. Overlapping
functionality arising from similar domain structures
would not be a very strong predictor for Mendelian dis-
eases, as genes with similar functions would not have
highly penetrant phenotypes. Genes with overlapping
functions may mask each other’s defects, be insufficient
to cause the disease alone, and perhaps only fractionally
increase the risk. In complex or polygenic disorders,
genes with overlapping functions that are mutated or
dysregulated may be more common, and hence predic-
tions by CMP may be more suited for gene discovery in
these disease states.
Performance on validation sets
Gentrepid was capable of replicating genes already
implicated by past genetic studies and the WTCCC
GWAS. For loci flagged by the GWA study that were
previously noted in OMIM, CPS successfully prioritised
the known disease genes. For the genes determined by
the WTCCC as likely candidates, either CPS or CMP
was capable of predicting the candidates. As the two
sets were generated from different genetic sources, it is
not unusual for the system to perform differently on
both. The known disease genes were determined
through family linkage analysis studies, but the WTCCC
gene validation set was generated from SNPs that are
population based. It may be that the known disease
genes are family specific or “private” and were not in
the population studied by the WTCCC. The WTCCC
candidates were selected by looking at the nearest
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genes, and not further, possibly missing other real can-
didates. Therefore differentiating false positives from
true positives is almost subjective.
Although the data were averaged across the seven
WTCCC phenotypes for this analysis, the performance of
the system is somewhat phenotype dependent. The strin-
gency threshold on some phenotypes has to be lower to
compensate for genetic heterogeneity in diseases such as
hypertension. For the autoimmune diseases where highly
significant results are within gene dense regions such as
the MHC locus or the cytokine cluster on human chro-
mosome 5, the identification of the causal gene cannot
be resolved through data mining analyses as all genes in
the region share similar functions and protein structures.
However the system does give some important informa-
tion in these instances by identifying the domain or path-
way that is being represented by the gene clusters, which
in the previous example are genes regulating immunity.
It is also important therefore to use all the genes within
the cluster for analysis, and hence the SNP/gene distance
based approach, as less common pathways within the
cluster may be important in the multiple loci analyses
that the system performs. The genetic and biological
complexity of the diseases is demonstrated in the raw
data from the GWA SNP analysis. To decipher this com-
plexity, the biomolecular and protein analysis automati-
cally detects commonality between multiple loci detected
and thus, to some extent, compensates for current statis-
tical genetic methods used on GWA data that test each
SNP is isolation from the others.
Comparison to other systems
Each method studied here has its strengths and weak-
nesses which should be kept in mind during use. For
instance, WebGestalt [37] looks for gene annotation
enrichment but does not take into account gene dupli-
cation found within the same locus. Gene clusters of
similar genes such as those in the MHC locus are given
equal weight as those from multiple regions and would
inflate particular results. GRAIL [36] and Gentrepid on
the other hand, correct for this by adjusting the calcula-
tions so genes from the same associated region are not
counted multiple times. Many of the GRAIL predictions
were made through the text of recent PubMed abstracts,
while fewer significant predictions were made with the
text prior to GWAS publications, indicating that the
results are mostly returning what we know and few de
novo candidates. In short, GRAIL is acting as a retrieval
tool. Gentrepid appears to be predicting novel candi-
dates with its functional domain-based approach. Also,
very few of the predictions overlapped between the dif-
ferent data sources used in each system. This empha-
sizes that one source of data may not be sufficient to
make candidate gene predictions and that using
alternate tools and data is wise, although these need to
be carefully tested and understood in isolation.
Several advantages of Gentrepid are: it allows analysis
of large datasets such as the MWS and WS set used in
this study; like GRAIL, Gentrepid allows users the flex-
ibility to enter genes or genome intervals, but uses dif-
ferent data sources for predictions. Gentrepid performs
similar enrichment analysis to WebGestalt but accounts
for multiple genes implicated from the same region.
Conclusions
In conclusion, we performed an extensive analysis of the
Gentrepid system using GWA data. The approach used
four sets of significant SNPs at different significance
thresholds. SNPs were mapped to the genome in six dif-
ferent ways and the resulting search spaces analysed
with the Gentrepid candidate gene prediction system.
The results show that using what is known about the
disease (seeded) as well as a blind approach (ab initio) is
beneficial in the discovery and prediction of candidate
disease genes. Further to this, using a less stringent SNP
association threshold allows true signals to be detected
which can be filtered using biomolecular information.
Also, when using gene selection approaches which
include genes that are not the nearest gene to the impli-
cated SNP, Gentrepid makes significant predictions
without unduly lowering the performance of the system.
As the predictions remain dependent on what we
already know in the protein knowledge base and on dis-
ease information, the system is only as good as the
underlying databases. Further detailed work on discov-
ery and annotation is required to take advantage of the
existing GWA data. We believe this method to be an
important tool in analysing GWAS as current methods
are less flexible and require more data processing.
Methods
WTCCC data
We obtained SNP data from the WTCCC [33] case-con-
trol studies of seven diseases: bipolar disorder (BD), cor-
onary artery disease (CAD), Crohn’s disease (CD),
hypertension (HT), rheumatoid arthritis (RA), type I dia-
betes (T1D) and type II diabetes (T2D). The WTCCC
GWAS used the Affymetrix chip set with approximately
500,000 known SNPs (Affy500k), with SNP positions
referenced to the human genome sequence assembly
from NCBI (build 35). We mapped these SNPs to
489,763 autosomal SNPs on the genome assembly (build
36.3), and 459,231 SNPs following WTCCC quality con-
trol [33].
OMIM known disease genes
We extracted known disease genes and loci from the
OMIM database [35] Morbid Map flat file by
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performing a text search for the disease name or parts
thereof. These were then manually filtered for relevant
loci.
Choice of SNP significance thresholds
An initial set of associated SNPs was filtered from the
summary data of SNPTEST [43], a program that per-
forms a series of association tests on the genotypes
obtained from the case-control studies. The p-value of
the trend test statistic (Cochran-Armitage test) [44] of
the additive genetic model was used as a test statistic
for SNP significance. The levels of significance chosen
as the SNP association thresholds were determined
using quantile-quantile (Q-Q) plots of the datasets
(Additional file 2, Figure S1). The Q-Q plots were con-
structed by plotting the observed -log10(pGWA) of the
SNPs against the expected -log10(pGWA), constructed
under the null hypothesis that there is no association
between the SNPs and the phenotype. Visual inspection
of the Q-Q plots shows the distribution of test statistics
of the observed SNPs for each phenotype begins to devi-
ate from the expected distribution under the null
hypothesis near pGWA ≈10
-2 and is distinctly different at
pGWA ≤ 10
-3.
Four different p-value thresholds were used to create
four associated SNP data sets for each phenotype: a
weakly significant set (WS, pGWA ≤ 10
-3), a moderately-
weak significant set (MWS, pGWA ≤ 10
-4), a moderately-
high significant set (MHS, PGWA ≤ 10
-5), and a highly
significant SNP set (HS, pGWA < 5 × 10
-7). The final HS
set is equivalent to the threshold used in the WTCCC
study, where the p-value was determined based on the a
priori probability of association, and not the typical mul-
tiple-comparison or Bonferroni correction [33].
SNPs within the sets were clustered based on physical
distance to one another through a naïve distance-based
clustering process: a SNP within 50 Kbp of another SNP
was considered to form a cluster. This value was chosen
based on the average size of haplotype blocks [45].
Construction of candidate gene search spaces
We used Gentrepid to predict and prioritise candidate
disease genes selected from phenotype-associated gene
sets generated from the SNP loci. Gene sets were con-
structed using one of two major assumptions: disease-
associated SNPs are either resident in, or adjacent to,
the disease gene; or the disease-associated SNPs may be
near, but not closest or adjacent to, the disease gene.
The first assumption we termed the nearest neighbour
gene selection approach (NN) and the second assump-
tion the bystander approach (BY).
For the NN approach, three sets of genes were cre-
ated: a set containing genes with SNPs internal to the
gene boundary defined by RefSeq [26], termed the
resident set; a second set with SNPs resident in the gene
or directly adjacent to it, termed the nearest set; and a
third set with the SNPs either resident in, or directly
adjacent to, the four nearest genes, termed the adjacent
set. The nearest set corresponds to the set commonly
selected by nearest neighbour approaches in most recent
GWAS [3]. In the adjacent set, genes on both strands of
the chromosome were considered in both the 5’ and 3’
direction. For both the nearest and adjacent sets the
physical distance between the SNP and the gene was
not used as a constraint.
For the BY approach, three intervals of different sizes
were tested. These values were chosen based on average
distances of transcriptional regulatory elements from the
genes they control [46,47]. Genes on both strands
around each of the SNPs were pooled from flanking
intervals of 0.1 Mbp, 0.5 Mbp or 1 Mbp in width.
SNP and gene density are non-uniform across the
genome and gene sizes vary, all of which influence the
number of positional gene candidates available for ana-
lysis. To test for bias due to SNP coverage by the Affy-
metrix chip set, we first checked the SNP distribution
across the genome. SNP positions and the frequency of
SNPs in different gene regions (exonic, intronic, UTRs)
and intergenic locations of the genome were calculated
by creating density plots. To determine if gene coverage
was affected by the various SNP-to-gene search space
construction assumptions, we calculated the percentage
of genes in the genome covered by SNPs on the
Affy500K chip set using each approach. We also wished
to determine if these genes were represented in Gentre-
pid by associated pathways and domains.
Prediction and prioritisation of candidate genes
To determine which SNPs are more likely to contribute
to the disease phenotype, a set of analyses were per-
formed using direct SQL queries of the in-house Gentre-
pid database https://www.gentrepid.org. Gentrepid’s two
modes of input, seeded mode and ab initio mode were
used to determine the common properties of pheno-
type-specific genes. Seeded mode is assisted by pheno-
type-associated genes from OMIM as seeds (Additional
file 1, Table S1). Ab initio mode uses only genes pooled
from the search spaces.
Genes in each data set were prioritised based on phe-
notype-associated common pathways (via CPS) and
common domains (via CMP). In previous work using
CPS, pathways containing at least two genes from dis-
tinct loci were ranked based on the total number of loci
involved, as described in George et al [16]. This is not
entirely satisfactory because it favours large pathways.
For instance, a pathway containing a large number of
genes may be selected over a more pertinent smaller
pathway or a subnet. To test the likelihood of a pathway
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being associated with a phenotype, genes were bi-parti-
tioned based on whether they were associated with (a)
the phenotype in question and (b) the pathway in ques-
tion. To calculate the significance, Fisher’s exact test
was performed using the fisher.test function in R http://
www.r-project.org/[48]. For CPS seeded and ab initio,
gene predictions were filtered based on the statistical
significance of the pathway using a threshold of ppath <
0.05, and prioritised based on the lowest p-value score
of the pathway they shared.
For CMP, the domains of phenotype-specific genes
were queried from the database and compared to
domains of other phenotype-specific genes in the data
set (ab initio) or domains of known disease genes
(seeded), as described in George et al [16]. For CMP
seeded, predictions are based on a pair wise similarity
score between the candidate and a known disease gene
between 0 (no similarity) and 1 (identical) [16]. Using a
benchmark set of oligogenic diseases with Mendelian
inheritance suggested by Turner et al [40], we pre-
viously determined that a pair wise similarity score of
0.4 between the test gene and the known disease gene is
a conservative threshold above which the test gene can
be considered a candidate [16]. Results above the
threshold score of 0.4 were filtered and prioritised. In
CMP ab initio mode, the domain combination was
tested for over-representation in the constructed inter-
vals compared to the genome as a whole through upper
and lower significance tests, based on a range of
expected values relating to domain correlation within
genes. The expected number of domains was calculated
based on the value of p, representing the extrema of the
level of correlation between domains in genes (pmin,
pmax), and more specifically the likelihood of occurrence
of the domain combination by chance [16]. Within a
gene, domain duplications are reasonably common [25]
leading to an anomalously low pmax. Thus a revised
pmax which ignores multiple copies of domains was cal-
culated to correct for this effect (pmax_unique). The gene
predictions were filtered on significance based on the
three c2 tests (c2min, c
2
max_unique and c
2
max). A c
2 value
greater than 7.88 is significant at the 0.005 level, but we
adopted more conservative values of c2max_unique ≥ 10
5
for multidomain proteins, and c2 min ≥ 102 for single
domain proteins. The predictions were then filtered
against random simulations described below to remove
false positives. Finally, the three c2 scores were corre-
lated with the random predictions using the Spearman’s
rank correlation coefficient test to choose the best
metric for prioritisation. Based on this test c2 min was
chosen.
As a control we selected random SNP sets of similar
size to the phenotype-specific data and mapped these to
genes using the same protocols described above (NN,
BY). The number of SNPs selected for each search
space was similar to the number of clusters formed by
the SNPs in the WTCCC data, and not the exact num-
ber of significant SNPs. This was done to account for
clusters in the phenotype-specific data due to linkage
disequilibrium or SNP-disease association. For each ran-
dom set, we ran Gentrepid CPS and CMP in both
seeded and ab initio modes, and tracked predictions and
significance scores. The randomization results were
averaged across 1000 replications.
Validation of predictions and metrics
We took several approaches to assess the ability of the
two Gentrepid modules to extract positional candidates.
Firstly, we studied the ability of Gentrepid to extract
and prioritise known disease genes and loci from the
phenotype data. When known disease genes were
employed as seeds for Gentrepid predictions, a leave-
one-out cross validation technique was used. In this
process, known disease genes were iteratively removed
as seeds during the prediction process, and the resulting
rank of the withheld gene was then assessed. The ranks
of known gene predictions in ab initio mode were also
calculated. Secondly, we assessed the Gentrepid results
against genes associated with the HS SNPs by the
WTCCC. Finally, predictions on the GWA-implicated
loci were compared to predictions made by Gentrepid
on the random data for the chosen levels of stringency
using both the NN and BY gene selection assumptions.
We calculated the specificity, sensitivity and enrichment
ratios for each of the validation sets as described in our
previous work [17] and also plotted ROC curves for an
overall comparison of the system (Additional file 3, Fig-
ure S2).
Comparison to other online methods
We selected GRAIL [36] and WebGestalt [37] as online
tools for comparison because they both take input from
GWAS data, and perform gene annotation enrichment
analysis similar to Gentrepid. GRAIL makes three inde-
pendent predictions using three different sources of
data: text mining of PubMed abstracts, Gene Ontology
(GO) annotations [49] or mRNA expression levels from
The Novartis Gene Expression Atlas [50]. Genes are
given a significance score [36]. WebGestalt performs
gene enrichment analysis on a user-defined gene/protein
list or a list of SNPs from typical GWAS arrays such as
those from Affymetrix or Illumina. The analysis is per-
formed by searching for enrichment of gene annotations
from GO, pathways from KEGG, Wikipathways and
Pathway commons, transcription factor binding site
motifs and microRNA target enrichment. Genes are not
individually ranked, but a p-value is calculated for every
annotation returned as a result [37].
Ballouz et al. BMC Genetics 2011, 12:98
http://www.biomedcentral.com/1471-2156/12/98
Page 17 of 20
To use a standard set of genes across all three tools,
we had to utilize the GRAIL gene search space as it was
the most restrictive. The GRAIL gene search space is
generated automatically from a user-defined list of SNPs
according to the linkage disequilibrium of the associated
locus. For each disease, we uploaded the list of asso-
ciated significant SNPs for the HS and MHS set. GRAIL
performs LD mapping and returns a list of query genes.
This LD gene list was then used as input for both Gen-
trepid and WebGestalt.
We ran GRAIL using the PubMed Text 2006 and
2011, GO 2006 and Novartis databases. A seeded search
can also be performed in GRAIL by including genomic
regions known to be associated with the disease. We
used the OMIM set defined earlier as the known gene
set and ran queries on the same databases. For each
gene in the search space, we stored the prediction p-
values for each data source.
We ran WebGestalt enrichment analysis on the same
gene lists analyzed by GRAIL. We used the “hspaiens_-
genome” as the reference gene list for all enrichment
analyses and ran the web tool using the default settings,
except for the significance levels which were set to p <
0.05 (default of Top 10). We performed GO analysis,
KEGG analysis, Wikipathways analysis, Pathway Com-
mons analysis, transcription factor target analysis,
microRNA target analysis, and protein interaction net-
work module analysis. For each gene, we stored the
most significant p-value for each analysis. We consid-
ered two sets of predictions using thresholds signifi-
cance p-values of either 0.05 or 0.01.
We ran Gentrepid on the LD-mapped gene search
space, using both CPS and CMP in seeded and ab initio
mode. We stored the CPS p-values as the prediction p-
values. CMP scores were evaluated at scores of either
0.4 or 0.8 for seeded CMP, and c2 min scores of either
100 or 105 for ab initio CMP.
We then compared the p-values of the genes across all
the systems. We also calculated the specificity, sensitiv-
ity and enrichment ratios on the WTCCC validation set
and compared across the different methods.
Additional material
Additional file 1: Gentrepid validation gene sets and additional
benchmarking results.Table S1 OMIM phenotype associated genes
used as seeds for the seeded mode and as the known disease gene
validation set.Table S2 Genes included in the known validation set. Table
S3 Genes included in the WTCCC validation set. Table S4 Specificity,
Sensitivity and Enrichment ratios for validation sets across all phenotypes.
Table S5 LD versus naïve clustering. Table S6 Comparison of the number
of significant Gentrepid predictions between LD and adjacent gene
selection sets. Table S7 Total numbers of significant predictions across
Gentrepid, GRAIL and WebGestalt. Table S8 Specificity, Sensitivity and
Enrichment ratios for WTCCC validation set for Gentrepid, GRAIL and
WebGestalt.
Additional file 2: Figure S1 Q-Q plots of expected values of the
associated trend test p-values versus observed generated for each
phenotype in black and uniform distribution in grey.
Additional file 3: Figure S2 ROC curves for Gentrepid on known and
WTCCC validation sets. CPS is represented by the dashed lines, CMP by
the filled lines. The colors indicate the SNP-to-gene mapping set used.
The first column from the left are the results for the known validation set
using seeded mode, The second column are the known validation set
under ab initio. The third column is the WTCCC validation set seeded
results. And the fourth column the WTCCC set, ab initio. The top panels
are the HS sets. The next set of panels the MHS set, the third MWS and
the bottom panels the WS set. The grey line in each plot represents
what a random guess should give. CPS is above the line for most cases.
CMP is below. CPS with the 0.1 Mbp or adjacent set performs the best.
List of abbreviations
GWAS: Genome-wide association studies; WTCCC: Wellcome Trust Case-
Control Consortium; CPS: common pathway scanning; CMP: common
module profiling; BD: Bipolar disorder; CAD: Coronary artery disease; CD:
Crohn’s disease; HT: Hypertension; RA: Rheumatoid arthritis; T1D: Type I
diabetes; T2D: Type II diabetes; NN: Nearest neighbour approach; BY:
Bystander approach; WS: Weakly significant set; MWS: Moderately-weak
significant set; MHS: moderately-high significant set; HS: highly significant
set.
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